Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Vigilant Algorithmic Monitoring of Software (VAMOS)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Computer science and informatics
Panel description: Informatics and information systems, computer science, scientific computing, intelligent systems
Countries involved: Austria
Call: ERC ADVANCED GRANT (ERC-2020-ADG, 2020)
Start date: 2022-01-01
End date: 2026-12-31
Duration (months): 60.0
Total project cost (EUR): 2451281.0
EU funding (EUR): 2451281.0
Participants: 1
Project status: SIGNED

We propose a theoretical basis and systems support needed to turn algorithmic monitoring from a runtime tool in the arsenal of formal methods into a pervasive and trusted engineering paradigm for the deployment of software. The ever-growing number of computational resources (many-core processors, data centers) allows software algorithms–decision makers–to be paired up with software monitors–decision checkers–where each monitor watches an algorithm in real time and provides warnings or intervenes when anything undesirable is observed. In order to be trusted, monitors are designed and linked independently of the monitored software. Monitoring is fundamentally a “best-effort” endeavor: it does not require complete specifications, nor perfect accuracy, but its widespread adoption requires a theory for the analysis of cost-precision trade-offs. Compared to the mature theories of computability and complexity (what can be computed? at what cost?), the theory of monitorability (what can be monitored, at what precision and cost?) is underdeveloped. We develop a quantitative, fine-grained resource and approximation theory for monitoring which supports the synthesis of monitors with desired cost-precision profiles. Our monitors can track the safety of systems as well as the fairness of algorithms (i.e., the absence of bias), security policies, and statistical properties of software. In addition, we facilitate the engineering paradigm of algorithmic monitoring by implementing systems support for the automated monitoring of software that is difficult to verify, such as algorithms that rely on neural networks, computations that happen in the cloud, and electronic systems that interface with the physical world (e.g., software for controlling medical and transportation devices). In all of these domains, the systematic and independent monitoring of critical requirements and sensitive statistics will significantly enhance trust in algorithmic decisions and digital systems.

Keywords: runtime verification
'Mad for Him'. Women, Religion and Mental Illness in the Late Middle Ages and in the Early Modern Age (WoMent)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Global Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Italy,Canada,Holy See (Vatican City State)
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2019-10-01
End date: 2022-07-31
Duration (months): 34.0
Total project cost (EUR): 242920.48
EU funding (EUR): 237768.0
Participants: 3
Project status: CLOSED

This research will analyse the biographical and autobiographical texts of late-medieval and early modern women who were deemed to be mystics, blessed, or saints. The main objective is to determine to what extent extreme religious experiences (ecstasies, visions, physical sensations) might be attributable not to unexplainable relations with the Godhead, but to very explainable medical causes. What their contemporaries saw as mystical experiences can, from our modern perspective, be characterized in medical terms. Questions at the basis of the project are, therefore: what is the boundary between illness and sanctity? Is it possible to draw a demarcation line between alleged miracles and mental illness? What do biographical texts tell us about this? Where, how, and when have these texts come down to us and who has transmitted them? This research will consider five cases of mental illnessess (anorexia, visions, hysterical pregnancies, folie à deux and post-partum depression) in biographical texts of six religious women: St.Lutgardis of Aywières †1246, St.Angela of Foligno †1309, the Bl.Giustina of Arezzo †1319, St.Margareta Ebner †1351, Margery Kempe †1438, Bl.Colomba of Rieti †1501. These six women may well illustrate a broad spectrum of diseases. This research is important because: a) biographical texts that reveal how women saints lived their daily lives marked by ecstasies and mental alterations, that have not yet been fully investigated; b) similar studies exist, but they focused only on a single nervous disease and were limited mostly to Italian women saints; c) current studies have not taken into account the fundamental iconographic sources.

Keywords: women,religion,mental illness,middle ages,early modern age
CACTUS es, the smart and comprehensive energy efficiency suite software and services based on artificial intelligence (CACTUSes)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: France
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2019-03-01
End date: 2019-08-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Automatique & Industrie (A.I.) presents a comprehensive service and tool named CACTUS Energy Suite (CACTUSes) designed for improving energy efficiency in the industry, large buildings and infrastructures, responding to the requirements of ISO 50001 and offering an intelligent and complete engineering approach to meet customers' needs and obligations . CACTUSes is an outstanding all-in-one, open source-technology based software package incorporating artificial intelligence, making energy management easy and cost-effective together with perfect implementation on clients' premises by A.I. specialists. It can be implemented as SaaS or locally, for data safety reasons. The features reach from data collection and treatment as a support for ISO 50001 Energy Management System process, via data reconstruction, to facilitating Energy Performance Indicators-based energy reviews, virtual meters. A.I.'s implementation based on energy engineering expertise and assistance completes the software. The return on investment due to energy savings brought by CACTUSes is less than 2 years. CACTUSes has been developed since 2011 and has now reached TRL9. Due to ever growing demand, A.I. seizes the opportunity to bring this innovative approach to the European market that will increase, and is expected to reach some EUR 200-300 M in 2030. A.I. targets 10% of market share in the EU starting with countries that have to implement Energy Management Systems (EnMS) starting with the frontrunners of the ISO 50001 implementation. With a SME Instrument Phase 1 cofinancing, we shall refine the market study and business plan. Phase 2 cofinancing will be dedicated to setting up the commercialisation strategy, salesforce and distribution channels as well as to finalising some technical features. CACTUSes sales are expected to exceed EUR 20 M by 2030 and the leverage factor of a future SME Instrument Phase 2 cofinancing will exceed 15 over 15 years.

Keywords: data correction,energy savings
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia (HAP2)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: Research and Innovation actions
Countries involved: Spain,Switzerland,Greece,France,France,Netherlands,United States
Call: Stratified host-directed approaches to improve prevention, treatment and/or cure of infectious diseases (H2020-SC1-2019-Two-Stage-RTD, 2019)
Start date: 2020-01-01
End date: 2024-12-31
Duration (months): 60.0
Total project cost (EUR): 9996350.25
EU funding (EUR): 9996350.25
Participants: 13
Project status: SIGNED

“HAP2” aims to develop stratified host-directed drugs and biomarkers to enhance the prevention and the treatment of hospital-acquired pneumonia (HAP) and develop precision medicine in infectious diseases. HAP is an infectious disease of major concern in the world, and the most frequent cause of hospital-acquired infections with 500,000 episodes being treated every year in Europe. Despite the development of European recommendations, the incidence remains high, with dramatic medical consequences: existing therapies and preventive measures do not result in the expected favourable outcome (clinical cure and survival) for 30% of patients. HAP are moreover the main cause of antibiotic consumption in European hospitals and are increasingly induced by drug-resistant pathogens. New, alternative and more effective host-targeted strategies are therefore urgently needed to fight antibiotic resistance. The ambition of “HAP2” is to revolutionize the management of HAP: capitalising on the novel concept of critical-illness related immunosuppression altering the host-pathogens interactions, we propose a complete reappraisal of the physiopathology of HAP based on the concept of respiratory dysbiosis. “The HAP2” project will reach two ground-breaking objectives in the field of bacterial infections: first the development of host-targeted approaches for the prevention and the treatment of a severe bacterial infection through the supplementation of the IL-12/IFN-γ axis which is defective in patients at risk of pneumonia; second the development of a clinico-biological score based on an integrative assessment of the host-pathogen interactions and genetic variation, to predict the course of HAP and the response to treatment. Our interdisciplinary consortium, bringing together 10 partners from academia and industry with expertise in clinical trials, immunology, microbiome analysis, omics and social sciences is uniquely placed to achieve this ambition within this 5-year project.

Keywords: hospital acquired pneumonia,nosocomial infections,immunotherapy,interleukin 12,interferon gamma,clinical trials,biomarker,host pathogen interactions,microbiome,bacterial drug resistance
Sustainable Valorization Of The Algae Industry Waste-Stream Within An Advanced Clean Technologies-Based Integrated Biorefinery Concept (ALGWAS-BIOR)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Career Restart panel
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Spain
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2021-01-21
End date: 2024-05-11
Duration (months): 36.0
Total project cost (EUR): 259398.72
EU funding (EUR): 259398.72
Participants: 1
Project status: SIGNED

The management of the growing amount of food waste is considered as an urgent environmental and economic burden by the European Commission. In response to this challenge, the Algwas-Bior Project proposes an integrated Biorefinery technology, focusing on the valorization of the waste stream released from the algae industry following agar extraction Gelidium sesquipedale. The hydrocolloid-centric extraction of this seaweed generates a large quantity of waste rich in organic materials and biologically active compounds. In Europe, a modest focus has been accorded so far to the industrial valorization of these compounds, particularly for the development of value-added food additives, pharmaceutical ingredients, and health-promoting products. The cascade technology will be a versatile solution adaptable to a wide range of food industry waste-stream valorization, thus, moving up the waste hierarchy through coupling the biomass and production sector in a solid circular Bioeconomy. The methodology combines high-quality process performance data generation supported by automated data acquisition and process control systems along with cutting edge analytical methods. The interdisciplinary concept mostly based on supercritical and subcritical fluids technologies, expanded to modern, clean technologies will be subjected to pilot-scale testing and process validation using the facilities of Hiperbaric as a secondment. The proposal will deliver state-of-the-art training to the researcher in these technologies within a three-way transfer of knowledge with the host institution and industrial partners. The results will lead to the development of commercialisable process that will reinforce the competitiveness of the food industry and will contribute to the strategy of the European Union to build a strong circular and bio-economy leading to the creation of viable green job opportunities.

Keywords: algae industry waste stream,sustainable valorization,integrated biorefinery,clean technology,approach,bioactive compounds,supercritical fluids,subcritical treatment,value added bioproducts
Rapid interaction profiling of 2019-nCoV for network-based deep drug-repurpose learning (DDRL) (RiPCoN)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: Research and Innovation actions
Countries involved: Spain,Germany,France
Call: Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic (H2020-SC1-PHE-CORONAVIRUS-2020, 2020)
Start date: 2020-04-01
End date: 2024-01-31
Duration (months): 46.0
Total project cost (EUR): 1230635.0
EU funding (EUR): 1230635.0
Participants: 3
Project status: SIGNED

We aim to identify approved drugs that can be repurposed for the treatment of 2019-nCoV using interactome profiling and deep-learning. We will deploy rapid high-throughput protein-protein interaction mapping and computational protein-RNA interaction predictions to chart the coronavirus host interactome network (CoHIN), which will become a public resource for translational and basic coronavirus research few months after project start. CoHIN will serve as input into an existing deep-learning model to identify approved drugs that are likely effective against 2019-nCoV, which will be validated in in vitro and in vivo systems. In the second stage we will experimentally determine the matrix of viral protein alleles vs. variants of the interacting human proteins to understand how human and viral natural variations jointly mediate disease severity in different individuals. These data will be integrated with epidemiological and human genomics data to improve risk management and improve preparedness for future coronavirus outbreaks. Overall, we aim to achieve the following objectives: - Map the protein interactome of 2019-nCoV and related Coronaviridae with their human host - Generate the allele interaction matrix and relate differences to epidemiological data - Develop a microarray-based patient screen to detect exposure to 2019-nCoV and identify immunogenic epitopes - Identify 10 approved drugs that are most likely efficient against 2019-nCoV using network integration and deep-learning - Validate drug candidates in in vitro and in vivo systems

Keywords: virus network drug repurpose deeplearning molecular interaction profiling protein interaction
FINISHING LEATHER WITH BIOPOLYMERS ADDED WITH NANOCOMPONENTS (FILE.BIO)

Framework: Horizon 2020 — Societal Challenges
Programme: Climate action, environment,  resource efficiency and raw materials
Action type: SME instrument
Countries involved: Italy
Call: Boosting the potential of small businesses for eco-innovation and a sustainable supply of raw materials (H2020-SMEINST-1-2015, 2015)
Start date: 2016-03-01
End date: 2016-06-30
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The goal of FILE.BIO project is to reduce the negative effects on the environment that derive from industrial finishing operations on leather, which constitute one of the most polluting industrial processes in the leather production cycle. This result will be obtained by developing a totally new family of supplementary products that are specifically designed for finishing. The products will contain naturally-derived polymers (biopolymers) instead of synthetic compounds (derived from petroleum), which are known for their great environmental impact. In particular, we will develop new biopolymer resins that replace the synthetic compounds currently used by tanners. In order to obtain better performance than what is currently possible with synthetic polyurethane compounds treated with other materials, we will use specific nano-materials for improving the mechanical and hydrophobic properties that the new finishing products impart to treated leather. Another important effect of our project will be a major improvement in work conditions at the factories where leather is finished. The goal of our project is to replace 30% of the presently petroleum based substances (approx. 10,000 tons) with chemicals of natural origin that have a low environmental impact and can improve the properties of the leather. 1.5 tons of petroleum are required for producing one ton of synthetic resins: our project will thus have the effect of reducing the consumption of petroleum in Europe by around 15 thousand tons. Overall, our project will have the potential of the following environmental benefits on the European level: 1) up to a 30% decrease (equivalent to 10 thousand-ton) in the amount of synthetic, potentially pollution substances used in the tanning processes; 2) up to a 30% reduction (equivalent to 15 thousand-ton) in petroleum consumption, in the tanning process; 3) a significant improvement in the work environment of approx. 35,000 persons.

Keywords: biopolymers,nanocomponents,finishing operations,leather,raw materials,saving,zein,tannery,supplementary products
ELIMINATION OF PARASITIC COPEPOD IN FARMED SALMON (NAUPLIUS)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Theme: Cross-cutting marine and maritime research
Action type: SME instrument
Countries involved: Spain
Call: Supporting SMEs efforts for the development - deployment and market replication of innovative solutions for blue growth (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2017-02-01
End date: 2017-07-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Salmon farming is a big industry with ca. 14,000 mill. € per year in the world., mainly in Norway and Chile. One of the greatest problems for salmon farming is the parasitic copepod, a sea-lice which hangs in the fish avoiding its growth, producing wounds and even the death. It causes a cost of 300 mill. € per year in Europe. Nowadays the fight against this parasite is the use of chemicals and drugs. It goes against the organic farming and the companies general interest because of the lost of increasing organic market, the bad image of salmon farming and its elevated cost. Other negative impacts in environment and natural fish stocks can also be found. The project deals with an innovative method for sea-lice elimination in salmon farms. It is the use of invertebrate filter feeders which eat the parasitic copepod in its early free-living planktonic stage. It avoids the parasitic copepod reachs its adulthood in the parasitic stage when it hangs in the fish. The method is totally environmental friendly, organic farming compatible and cost-effective. Preliminary cost analysis shows a 25% of cost savings and it might also coproduce commercial filter feeders in the same salmon farm. Moreover the method is almost totally developed, having reached a TRL 8 after laboratory, pilot scale and operational environment demonstration.

Keywords: salmon,aquaculture,parasites,copepod,filter feeder
ERA-NET on cardiovascular diseases to implement joint transnational research projects and set up international cooperations (ERA-CVD)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: ERA-NET Cofund
Partnership: ERA-CVD (ERA-NET)
Countries involved: Estonia,Austria,Germany,Italy,Israel,Spain,Germany,Taiwan, Province of China,Norway,Poland,Romania,Slovenia,Türkiye,Belgium,Slovakia,Latvia,France,Netherlands,Portugal
Call: ERA-NET: Cardiovascular disease (H2020-HCO-2015, 2015)
Start date: 2015-10-01
End date: 2022-12-31
Duration (months): 87.0
Total project cost (EUR): 19103750.0
EU funding (EUR): 5974237.5
Participants: 25
Project status: CLOSED

Cardiovascular diseases (CVD) are the largest cause of death in the EU and account for around 2 million deaths per year. Overall, CVD are estimated to cause the economy of the EU costs of almost 196 billion Euros a year. Furthermore, they are one of the leading causes of long term sickness, chronic diseases and loss to the labour market. Therefore, CVD are a major health problem in Europe. Despite the overall burden of CVD on European citizens and national health systems, translational cardiovascular research is fragmented and mainly occurs at national levels. However, the present and future challenges in cardiovascular research can only be met by an effective cooperation at transnational level. Therefore, the proposed European Research Area Network on cardiovascular diseases (ERA-CVD) aims to coordinate national and regional programmes for translational research in the area CVD by implementing one Joint Transnational Call (JTC2016) with EU Co-funding followed by further non-co-funded JTC (2017-2019). Although this consortium will be newly established, a collaboration and alignment of national programmes and activities has already been achieved during the preparation of the ERA-Net Co-fund proposal. This process is supported by CardioScape an EU-funded survey of the European cardiovascular research landscape coordinated by the European Society of Cardiology (ESC). The current ERA-CVD proposal will extend and strengthen the transnational cooperation of the current 23 ministries/institutions/foundations from 18 European, associated and third countries. Furthermore, ERA-CVD plans to cooperate with the ESC and the European Heart Network (EHN). Moreover, the collaboration with European Research Infrastructures, e.g. the ESFRI-initiatives is intended in order to set up an efficient European framework for innovative transnational research on CVD. Also the extension of the consortium and international collaborations are intended.

Keywords: era net,cofund,cardiovascular diseases,collaboration,harmonization,joint transnational calls,translational research